Relationship between TIMP-3, DNMT1 and disease progression and prognosis in patients with breast cancer

Abstract

Abstract: Objective To analyze the association between matrix metalloproteinase tissue inhibitor 3 (TIMP-3), DNA methyltransferase 1 (DNMT1) and the disease progression and prognosis of breast cancer patients. Methods A retrospective analysis was conducted on the clinical data of 102 breast cancer patients admitted to Xinyang Central Hospital from March 2022 to March 2024. The correlations between TIMP-3, DNMT1 and tumor markers in breast cancer patients were analyzed, as well as their predictive efficacy for adverse prognosis of breast cancer. Results The expression score of TIMP-3 in the late stage group was lower than that in the middle stage group, and the expression score of DNMT1 in the early stage group was higher than that in the middle stage group and the early stage group (P<0.05). The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA153), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA199) and tissue polypeptide antigen (TPA) in the late group were higher than those in the middle group and early group (P<0.05). TIMP-3 was negatively correlated with CEA, CA153, CA125, CA199 and TPA (P<0.05). DNMT1 was positively correlated with CEA, CA153, CA125, CA199 and TPA (P<0.05). The poor prognosis group had a significantly lower expression score of TIMP-3 and a significantly higher expression score of DNMT1 than the good prognosis group (P<0.05). The AUC value of TIMP-3 and DNMT1 combined detection in predicting poor prognosis of breast cancer was higher than that of TIMP-3 or DNMT1 alone. Conclusion The combined detection of TIMP-3 and DNMT1 can serve as an important auxiliary method for identifying patients with poor prognosis.

Key words: breast cancer, tissue inhibitor of matrix metalloproteinase 3, DNA methyltransferase 1, disease progression, prognosis

摘要： 目的分析基质金属蛋白酶组织抑制因子3（TIMP-3）、DNA甲基转移酶1（DNMT1）与乳腺癌患者病情进展及预后情况的关联。方法回顾性分析信阳市中心医院2022年3月—2024年3月收治的102例乳腺癌患者临床资料,分析TIMP-3、DNMT1与乳腺癌患者肿瘤标志物的相关性,及对乳腺癌不良预后的预测效能。结果晚期组的TIMP-3表达评分低于中期组、早期组,DNMT1表达评分高于中期组、早期组（P<0.05）。晚期组的癌胚抗原（CEA）、糖类抗原15-3（CA153）、糖类抗原125（CA125）、糖类抗原19-9（CA199）、组织多肽抗原（TPA）均高于中期组、早期组（P<0.05）。TIMP-3与CEA、CA153、CA125、CA199、TPA负相关（P<0.05）。DNMT1与CEA、CA153、CA125、CA199、TPA正相关（P<0.05）。预后不良组的TIMP-3表达评分低于预后良好组,DNMT1表达评分高于预后良好组（P<0.05）。TIMP-3、DNMT1联合检测对乳腺癌不良预后的预测AUC值高于TIMP-3、DNMT1单独检测。结论联合检测TIMP-3、DNMT1可作为识别患者不良预后的重要辅助手段。

关键词: 乳腺癌, 基质金属蛋白酶组织抑制因子3, DNA甲基转移酶1, 病情进展, 预后

CLC Number:

R737.9

CHENG Qingqing, LI Xiongwei. Relationship between TIMP-3, DNMT1 and disease progression and prognosis in patients with breast cancer[J]. Journal of Chengde Medical University, 2026, 43(3): 197-201.

程青青, 李雄伟. TIMP-3、DNMT1与乳腺癌患者病情进展及预后的关联[J]. 承德医学院学报, 2026, 43(3): 197-201.

Add to citation manager EndNote|Ris|BibTeX

URL: https://tougao.cdmc.edu.cn/EN/

https://tougao.cdmc.edu.cn/EN/Y2026/V43/I3/197

References

[1] Katsura C, Ogunmwonyi I, Kankam HK, et al.Breast cancer: presentation, investigation and management[J]. Br J Hosp Med (Lond), 2022, 83(2): 1-7.
[2] 牛振宇,田晶. 靶向调节肿瘤微环境治疗乳腺癌的研究进展[J]. 华夏医学,2022,35(3):123-129.
[3] Lee WT, Wu PY, Cheng YM, et al.Tissue inhibitor of metalloproteinase 3: unravelling its biological function and significance in oncology[J]. Int J Mol Sci, 2024, 25(6): 3191.
[4] Li Y, Wang J, Zhou L, et al. DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity[J]. Sci Immunol, 2025, 10(105): eadm8251.
[5] 中国抗癌协会乳腺癌专业委员会,中华医学会肿瘤学分会乳腺肿瘤学组,邵志敏. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志,2023,33(12):1092-1186.
[6] 田甜,云昊,王山,等. 乳腺癌肿瘤全域的表观扩散系数信号强度直方图与病理分期的关系及对复发的预测价值[J]. 中国CT和MRI杂志,2023,21(2):98-101.
[7] 鲍娇玉,刘存,陈文君,等. 1990—2021年中国女性乳腺癌疾病负担趋势及危险因素分析[J]. 肿瘤预防与治疗,2025,38(2):98-106.
[8] 黄果,魏雪峰,白飞,等. 我国3省份三甲医院医师对乳腺癌病理切片AI辅助诊断技术的评价及其影响因素[J]. 医学与社会,2025,38(1):118-125.
[9] Balkenenge L, Teuwen J, Mann RM.Application of deep learning in breast cancer imaging[J]. Semin Nucl Med, 2022, 52(5): 584-596.
[10] 吴如珍,林学军,刘彩银,等. 基于CiteSpace软件的乳腺癌影像学研究现状及热点可视化分析[J]. 医疗装备,2025,38(1):1-5,22.
[11] 李和丽,梁殿迅,王秋宇,等. miR-21靶向调节TIMP3/MMP9信号通路对宫颈癌细胞增殖、凋亡和迁移的影响[J]. 中国老年学杂志,2023,43(23):5800-5804.
[12] 郭超,法楠,黄景涛,等. 肺腺癌中DNMT1表达和TFF1甲基化水平的相关性及临床意义[J]. 河北医学,2025,31(3):420-425.
[13] 宋以宁,史明明,陈文信,等. Ki-67在乳腺癌及腋窝转移淋巴结中的表达及临床应用[J]. 山东第二医科大学学报,2024,46(6):401-406.
[14] 于娇,李汉杰,陈鑫,等. 乳腺癌组织中TIMP-3及DNMT1的表达与患者预后的相关性[J]. 现代肿瘤医学,2024,32(17):3248-3253.
[15] 武坤,黄佳莉,程沈菊,等. 敲除DNMT1增强NK细胞对急性髓细胞白血病的抑制作用[J]. 中国实验血液学杂志,2025,33(3):653-659.